var data={"title":"Chediak-Higashi syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chediak-Higashi syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/contributors\" class=\"contributor contributor_credentials\">E Richard Stiehm, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/contributors\" class=\"contributor contributor_credentials\">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/contributors\" class=\"contributor contributor_credentials\">Elizabeth TePas, MD, MS</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 20, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chediak-Higashi syndrome (CHS; MIM #214500) is a rare, autosomal recessive disorder characterized by recurrent pyogenic infections, partial oculocutaneous albinism, progressive neurologic abnormalities, mild coagulation defects, and a lymphoma-like accelerated phase termed hemophagocytic lymphohistiocytosis (HLH) [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/1-5\" class=\"abstract_t\">1-5</a>].</p><p>A mouse model of CHS, with an altered &quot;beige&quot; coat color, has been an important source of information on the disease [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/6-9\" class=\"abstract_t\">6-9</a>]. The gene responsible for this defect was first discovered in the mouse model and is called Beige. It and the defective human gene, called <em>CHS1</em><span class=\"nowrap\">/<em>LYST</em>,</span> are part of the BEACH family of vesicle trafficking regulatory proteins.</p><p>The diagnosis of CHS can be made by examination of a peripheral smear for pathognomonic giant cytoplasmic granules in leukocytes and platelets. Hematopoietic cell transplantation (HCT) is the treatment of choice.</p><p>This topic will review the pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of CHS. An overview of primary disorders of phagocytic function is presented separately. (See <a href=\"topic.htm?path=primary-disorders-of-phagocytic-function-an-overview\" class=\"medical medical_review\">&quot;Primary disorders of phagocytic function: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CHS is a rare disorder. The exact incidence is unknown. Less than 500 cases have been reported worldwide in the past 20 years [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/6\" class=\"abstract_t\">6</a>]. Parental consanguinity is common.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The underlying defect in CHS is abnormal organellar protein trafficking that is suspected to lead to aberrant fusion of vesicles and failure to transport lysosomes to the appropriate site of action [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/7\" class=\"abstract_t\">7</a>]. This defect is due to a mutation in the lysosomal trafficking regulator (<em>CHS1</em><span class=\"nowrap\">/<em>LYST</em>)</span> gene at 1q42.1-2 (MIM #214500) [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Most mutations are nonsense or null mutations, resulting in an absent <span class=\"nowrap\">CHS1/LYST</span> protein [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. Milder forms of CHS have been reported with missense mutations that probably encode a partially functioning protein.</p><p>The <span class=\"nowrap\">CHS1/LYST</span> protein is widely expressed in the cytosol [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/7\" class=\"abstract_t\">7</a>]. Its exact function is unknown. It is postulated that the biochemical defect in CHS is due to decreased levels of protein kinase C [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/10-13\" class=\"abstract_t\">10-13</a>].</p><p>Altered <span class=\"nowrap\">lysosomes/granules</span> are found in all cell types in CHS and are the hallmark of the disease (<a href=\"image.htm?imageKey=ALLRG%2F57556\" class=\"graphic graphic_picture graphicRef57556 \">picture 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Melanocytes contain enlarged pigment granules (melanosomes) that are not appropriately transferred to keratinocytes or epithelial cells, resulting in partial oculocutaneous albinism [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/14,15\" class=\"abstract_t\">14,15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neutrophils have giant azurophilic granules [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/16\" class=\"abstract_t\">16</a>], and cytotoxic T cells have enlarged mature secretory cytolytic granules [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/17,18\" class=\"abstract_t\">17,18</a>]. These abnormal granules do not appropriately release their contents in the setting of bacterial or viral infections, leading to impaired bactericidal and cytotoxic function. Neutrophils also have impaired chemotaxis [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The number of platelet-dense bodies (serotonin-storage granules) is significantly reduced, resulting in a platelet storage pool deficiency and bleeding diathesis [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/20-22\" class=\"abstract_t\">20-22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Plasma membrane repair, which is a lysosome-mediated process, is also impaired [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients are typically identified in infancy or early childhood when they present with partial oculocutaneous albinism (OCA2 type) and recurrent pyogenic infections [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/6\" class=\"abstract_t\">6</a>].</p><p>The degree of hypopigmentation varies, but most patients have fair skin and sparse light blond, gray, or white hair that often has a metallic sheen (<a href=\"image.htm?imageKey=ALLRG%2F75571\" class=\"graphic graphic_picture graphicRef75571 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/24\" class=\"abstract_t\">24</a>]. Speckled hyperpigmentation and hypopigmentation of sun-exposed areas may be seen in more darkly pigmented races [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/25\" class=\"abstract_t\">25</a>]. Pigmentation of the irides and retinae is also reduced [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/26\" class=\"abstract_t\">26</a>]. Patients have light-colored, usually blue, eyes. Ocular manifestations include photophobia, decreased visual acuity, nystagmus, and strabismus.</p><p>Pyogenic infections are frequent and severe. The most common sites of infection are the skin, respiratory tract, and mucous membranes. Cutaneous infections range from superficial pyoderma to deep abscesses and ulcerations [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/27\" class=\"abstract_t\">27</a>]. The deeper lesions heal slowly and leave atrophic scars. The most common causative organism is <em>Staphylococcus aureus</em>. <em>Streptococcus pyogenes</em> and <em>Pneumococcus</em> species are other common infectious organisms in CHS.</p><p>Gingivitis, oral ulcerations, and periodontal disease are common [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/28,29\" class=\"abstract_t\">28,29</a>]. Enterocolitis has also been reported [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/30\" class=\"abstract_t\">30</a>]. Renal function impairment is reported in animals with the disease [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/31\" class=\"abstract_t\">31</a>].</p><p>Patients also have a mild coagulation defect that results in easy bruising and abnormal bleeding, especially of mucosal tissue [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/20-22\" class=\"abstract_t\">20-22</a>]. Bleeding may become more severe during the accelerated phase. Hepatosplenomegaly and lymphadenopathy are common and become more pronounced during the accelerated phase.</p><p>Approximately 10 percent of patients survive early childhood, despite serious infections, but develop severe, debilitating neurologic manifestations in adolescence and early adulthood [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/32-36\" class=\"abstract_t\">32-36</a>]. Both the peripheral and central nervous systems are involved. Neurologic defects include weakness and sensory deficits due to peripheral neuropathy, ataxia, tremors, cranial nerve palsies, progressive intellectual decline, and seizures. Spinocerebellar degeneration, movement disorders such as Parkinson disease, and dementia also occur. Patients who survive to the second or third decade may be confined to wheelchair.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Accelerated phase</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients who do not die from infection eventually enter the &quot;accelerated phase&quot; of the disease, characterized by massive lymphohistiocytic infiltration of virtually all organ systems and an even more profound immune deficiency [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/37\" class=\"abstract_t\">37</a>]. Patients present in the accelerated phase with fever, increased hepatosplenomegaly and lymphadenopathy, and worsened pancytopenia and bleeding. This phase occurs in more than 80 percent of patients and is usually lethal.</p><p>The accelerated phase does not appear to be a true malignancy but rather is a form of familial hemophagocytic lymphohistiocytosis (HLH). It is thought to be triggered by viral infections, particularly the Epstein-Barr virus [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/7,38,39\" class=\"abstract_t\">7,38,39</a>]. Lack of natural killer (NK) cell function [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/40\" class=\"abstract_t\">40</a>], abnormal surface expression of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/41\" class=\"abstract_t\">41</a>], and reduced cytotoxic T lymphocyte (CTL) cytotoxicity [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/42\" class=\"abstract_t\">42</a>] may play a role in the development of the accelerated phase. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis#H543663\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of hemophagocytic lymphohistiocytosis&quot;, section on 'Clinical features'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">LABORATORY FINDINGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neutropenia is a common laboratory finding and is probably due to intramedullary destruction of neutrophils [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/43\" class=\"abstract_t\">43</a>]. Neutrophils and monocytes have decreased chemotactic responses [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/19\" class=\"abstract_t\">19</a>]. Intracellular killing of bacteria is also impaired [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/44\" class=\"abstract_t\">44</a>]. Natural killer (NK) cells are present, but NK cytotoxicity is nearly absent [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/45\" class=\"abstract_t\">45</a>]. Antibody-dependent cellular cytotoxicity is also decreased [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/17\" class=\"abstract_t\">17</a>]. B cell function is usually normal [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/40,46\" class=\"abstract_t\">40,46</a>]. Hypergammaglobulinemia is often seen, secondary to frequent infections [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/47\" class=\"abstract_t\">47</a>].</p><p>Patients with CHS have abnormal platelet aggregation and bleeding time [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/20,21\" class=\"abstract_t\">20,21</a>]. Thrombocytopenia is common in the accelerated phase [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/22\" class=\"abstract_t\">22</a>].</p><p>Diffuse atrophy of the brain and spinal cord is noted on computed tomography (CT) scan and magnetic resonance imaging (MRI) [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/48\" class=\"abstract_t\">48</a>]. There is also markedly delayed nerve conduction time on electromyography (EMG). An electroencephalography (EEG) may reveal seizure activity. Giant granules are seen in Schwann cells and muscle cells [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/33,49\" class=\"abstract_t\">33,49</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of CHS is made by examining a peripheral blood smear for the classic giant azurophilic granules in neutrophils, eosinophils, and other granulocytes (<a href=\"image.htm?imageKey=ALLRG%2F57556\" class=\"graphic graphic_picture graphicRef57556 \">picture 1</a> and <a href=\"image.htm?imageKey=HEME%2F71313\" class=\"graphic graphic_picture graphicRef71313 \">picture 3</a>). These large granules are found in all granule-containing cells, including peripheral blood and bone marrow cells, melanocytes, peripheral and central nerve tissue, renal tubular epithelium, fibroblasts, and gastric mucosa [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/50,51\" class=\"abstract_t\">50,51</a>].</p><p>The diagnosis may be confirmed by genetic testing for mutations in the <em>CHS1</em><span class=\"nowrap\">/<em>LYST</em></span> gene. The gene is large, and most mutations are unique. Thus, identifying the exact mutation can be a challenge.</p><p>While not typically needed for diagnosis, examination of skin melanocytes reveals giant melanosomes [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. Light microscopy of hair shafts shows small aggregates of clumped pigmentation that are irregularly distributed [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/52\" class=\"abstract_t\">52</a>]. Shafts appear bright and polychromatic under polarized light microscopy.</p><p>CHS can be diagnosed prenatally by examining amniotic or chorionic villus cells for enlarged lysosomes [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/53\" class=\"abstract_t\">53</a>]. The diagnosis may also be made by examination of a fetal blood sample or hair from a scalp biopsy.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Griscelli syndrome is a rare, autosomal recessive disorder characterized by partial oculocutaneous albinism and immunodeficiency [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/54\" class=\"abstract_t\">54</a>]. This disorder is due to a mutation in one of three intracellular trafficking genes. These patients do not have giant intracellular granules, unlike patients with CHS. Griscelli syndrome may also be distinguished from CHS by examination of hair shafts [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/52\" class=\"abstract_t\">52</a>]. Larger, irregular clumps of melanin granules are distributed mainly near the medulla of the hair shaft. The shaft appears uniformly white under polarized light microscopy. (See <a href=\"topic.htm?path=syndromic-immunodeficiencies#H8\" class=\"medical medical_review\">&quot;Syndromic immunodeficiencies&quot;, section on 'Griscelli syndrome'</a>.)</p><p>Hermansky-Pudlak syndrome (HPS) is a rare, autosomal recessive disorder characterized by partial oculocutaneous albinism and a platelet storage pool deficiency [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/55\" class=\"abstract_t\">55</a>]. Mutations in eight different genes are associated with HPS. These mutations lead to defects in cytoplasmic organelles involved in protein sorting and trafficking. HPS-2 is caused by a mutation in the <em>AP3B1</em> gene. Patients with HPS-2 have neutropenia and recurrent infections. Other types of HPS have associated pulmonary fibrosis and colitis [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/56,57\" class=\"abstract_t\">56,57</a>]. (See <a href=\"topic.htm?path=congenital-and-acquired-disorders-of-platelet-function#H29\" class=\"medical medical_review\">&quot;Congenital and acquired disorders of platelet function&quot;, section on 'Storage pool disorders'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CHS is treated with prophylactic antibiotics and aggressive therapy for acute bacterial infections (see <a href=\"topic.htm?path=primary-immunodeficiency-overview-of-management\" class=\"medical medical_review\">&quot;Primary immunodeficiency: Overview of management&quot;</a>). Granulocyte colony stimulating factor (G-CSF) has been used to correct neutropenia and decrease infection [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/58\" class=\"abstract_t\">58</a>]. Interferon-gamma may partially restore function of natural killer (NK) cells.</p><p>High-dose glucocorticoids and splenectomy have been used with some success to induce a transient remission in the accelerated phase [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/59\" class=\"abstract_t\">59</a>]. Intravenous gammaglobulin, antivirals (eg, <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>), and chemotherapy (eg, <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">vincristine</a>) have also been used to slow the accelerated phase [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/60\" class=\"abstract_t\">60</a>]. However, treatment with these agents is not curative, and the accelerated phase usually recurs in a more aggressive and difficult-to-manage form.</p><p>Hematopoietic cell transplantation (HCT), including cord blood transplants, is the treatment of choice to correct the immunologic and hematologic manifestations of CHS, although it does not affect the progressive neurologic deterioration or the oculocutaneous albinism [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/48,61,62\" class=\"abstract_t\">48,61,62</a>]. A deficiency or deterioration of cytotoxic T cell function may predispose to hemophagocytic lymphohistiocytosis (HLH) and is of use in determining the need for early HCT [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/42\" class=\"abstract_t\">42</a>]. Transplantation appears to be most successful if a human leukocyte antigen (HLA)-identical donor is used and if the transplantation is performed prior to the accelerated phase or during remission. However, even patients in the accelerated phase may benefit from transplantation [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/63\" class=\"abstract_t\">63</a>]. Successfully transplanted patients have improved NK cell function, no significant infections, and do not progress to, or have a recurrence of, the accelerated phase. In a 2013 report from Japan, five of six patients with CHS survived transplantation [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/64\" class=\"abstract_t\">64</a>]. HCT was performed prior to the accelerated phase in all six patients. Three additional children with CHS successfully underwent cord blood transplantation [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/65\" class=\"abstract_t\">65</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with CHS die from pyogenic infection before seven years of age if not transplanted. Hemorrhage is a less common cause of death. The five-year probability of survival posttransplantation was 62 percent in a review of 35 children with CHS [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/61\" class=\"abstract_t\">61</a>]. However, most transplanted patients and those few patients who survive childhood without transplantation develop neurologic deficits by the time they reach their early twenties [<a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/48\" class=\"abstract_t\">48</a>]. These deficits include cerebellar ataxia, with difficulty walking and loss of balance, tremor, peripheral neuropathy, and low cognitive abilities. These neurologic sequelae can be quite debilitating.</p><p class=\"headingAnchor\" id=\"H1481194276\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-primary-immunodeficiencies\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Primary immunodeficiencies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chediak-Higashi syndrome (CHS) is a rare, autosomal recessive disorder characterized by recurrent pyogenic infections, partial oculocutaneous albinism, progressive neurologic abnormalities, mild coagulation defects, and a lymphoma-like accelerated phase. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H4\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The defective gene, called <em>CHS1</em><span class=\"nowrap\">/<em>LYST</em>,</span> is part of the BEACH family of vesicle trafficking regulatory proteins. (See <a href=\"#H3\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who do not die from infection eventually enter the &quot;accelerated phase&quot; of the disease, characterized by massive lymphohistiocytic infiltration of virtually all organ systems. (See <a href=\"#H5\" class=\"local\">'Accelerated phase'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis is made by examination of a peripheral smear for pathognomonic giant cytoplasmic granules in leukocytes and platelets. (See <a href=\"#H7\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hematopoietic cell transplantation (HCT) may be performed to correct the immunologic and hematologic manifestations of CHS. Treatment with HCT prevents infections and the accelerated phase, but patients still develop neurologic deficits. (See <a href=\"#H9\" class=\"local\">'Treatment'</a> above and <a href=\"#H10\" class=\"local\">'Prognosis'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H865637202\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Robert L Roberts, MD, PhD and Kevin Yeh-Sheng Wang, MD, LAc, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/1\" class=\"nounderline abstract_t\">Karim MA, Suzuki K, Fukai K, et al. Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. Am J Med Genet 2002; 108:16.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/2\" class=\"nounderline abstract_t\">Beguez-Cesar AB. Neutropenia cronica maligna familiar con granulaciones atipicas de los leucocitos. Bol Soc Cuba Pediatr 1943; 15:900.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/3\" class=\"nounderline abstract_t\">CHEDIAK MM. [New leukocyte anomaly of constitutional and familial character]. Rev Hematol 1952; 7:362.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/4\" class=\"nounderline abstract_t\">HIGASHI O. Congenital gigantism of peroxidase granules; the first case ever reported of qualitative abnormity of peroxidase. Tohoku J Exp Med 1954; 59:315.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/5\" class=\"nounderline abstract_t\">SATO A. Ch&eacute;diak and Higashi's disease: probable identity of a new leucocytal anomaly (Ch&eacute;diak) and congenital gigantism of peroxidase granules (Higashi). Tohoku J Exp Med 1955; 61:201.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/6\" class=\"nounderline abstract_t\">Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Curr Opin Hematol 2008; 15:22.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/7\" class=\"nounderline abstract_t\">Perou CM, Leslie JD, Green W, et al. The Beige/Chediak-Higashi syndrome gene encodes a widely expressed cytosolic protein. J Biol Chem 1997; 272:29790.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/8\" class=\"nounderline abstract_t\">Barbosa MD, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996; 382:262.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/9\" class=\"nounderline abstract_t\">Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet 1996; 14:307.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/10\" class=\"nounderline abstract_t\">Morimoto M, Tanabe F, Kasai H, Ito M. Effect of a thiol proteinase inhibitor, E-64-d, on susceptibility to infection with Staphylococcus aureus in Chediak-Higashi syndrome (beige) mice. Int Immunopharmacol 2007; 7:973.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/11\" class=\"nounderline abstract_t\">Ito M, Tanabe F, Takami Y, et al. Rapid down-regulation of protein kinase C in (Chediak-Higashi syndrome) beige mouse by phorbol ester. Biochem Biophys Res Commun 1988; 153:648.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/12\" class=\"nounderline abstract_t\">Ito M, Sato A, Tanabe F, et al. The thiol proteinase inhibitors improve the abnormal rapid down-regulation of protein kinase C and the impaired natural killer cell activity in (Chediak-Higashi syndrome) beige mouse. Biochem Biophys Res Commun 1989; 160:433.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/13\" class=\"nounderline abstract_t\">Cui SH, Tanabe F, Terunuma H, et al. A thiol proteinase inhibitor, E-64-d, corrects the abnormalities in concanavalin A cap formation and the lysosomal enzyme activity in leucocytes from patients with Chediak-Higashi syndrome by reversing the down-regulated protein kinase C activity. Clin Exp Immunol 2001; 125:283.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/14\" class=\"nounderline abstract_t\">Zelickson AS, Windhorst DB, White JG, Good RA. The Chediak-Higashi syndrome: formation of giant melanosomes and the basis of hypopigmentation. J Invest Dermatol 1967; 49:575.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/15\" class=\"nounderline abstract_t\">Zhao H, Boissy YL, Abdel-Malek Z, et al. On the analysis of the pathophysiology of Chediak-Higashi syndrome. Defects expressed by cultured melanocytes. Lab Invest 1994; 71:25.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/16\" class=\"nounderline abstract_t\">Kjeldsen L, Calafat J, Borregaard N. Giant granules of neutrophils in Chediak-Higashi syndrome are derived from azurophil granules but not from specific and gelatinase granules. J Leukoc Biol 1998; 64:72.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/17\" class=\"nounderline abstract_t\">Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol 1995; 154:6122.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/18\" class=\"nounderline abstract_t\">Stinchcombe JC, Page LJ, Griffiths GM. Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak Higashi syndrome patients. Traffic 2000; 1:435.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/19\" class=\"nounderline abstract_t\">Clark RA, Kimball HR. Defective granulocyte chemotaxis in the Chediak-Higashi syndrome. J Clin Invest 1971; 50:2645.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/20\" class=\"nounderline abstract_t\">Buchanan GR, Handin RI. Platelet function in the Chediak-Higashi syndrome. Blood 1976; 47:941.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/21\" class=\"nounderline abstract_t\">Rendu F, Breton-Gorius J, Lebret M, et al. Evidence that abnormal platelet functions in human Ch&eacute;diak-Higashi syndrome are the result of a lack of dense bodies. Am J Pathol 1983; 111:307.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/22\" class=\"nounderline abstract_t\">Apitz-Castro R, Cruz MR, Ledezma E, et al. The storage pool deficiency in platelets from humans with the Ch&eacute;diak-Higashi syndrome: study of six patients. Br J Haematol 1985; 59:471.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/23\" class=\"nounderline abstract_t\">Huynh C, Roth D, Ward DM, et al. Defective lysosomal exocytosis and plasma membrane repair in Chediak-Higashi/beige cells. Proc Natl Acad Sci U S A 2004; 101:16795.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/24\" class=\"nounderline abstract_t\">Barak Y, Nir E. Chediak-Higashi syndrome. Am J Pediatr Hematol Oncol 1987; 9:42.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/25\" class=\"nounderline abstract_t\">Al-Khenaizan S. Hyperpigmentation in Chediak-Higashi syndrome. J Am Acad Dermatol 2003; 49:S244.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/26\" class=\"nounderline abstract_t\">Creel D, Boxer LA, Fauci AS. Visual and auditory anomalies in Chediak-Higashi syndrome. Electroencephalogr Clin Neurophysiol 1983; 55:252.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/27\" class=\"nounderline abstract_t\">Weary PE, Bender AS. Chediak-Higashi syndrome with severe cutaneous involvement. Occurrence in two brothers 14 and 15 years of age. Arch Intern Med 1967; 119:381.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/28\" class=\"nounderline abstract_t\">Delcourt-Debruyne EM, Boutigny HR, Hildebrand HF. Features of severe periodontal disease in a teenager with Ch&eacute;diak-Higashi syndrome. J Periodontol 2000; 71:816.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/29\" class=\"nounderline abstract_t\">Bailleul-Forestier I, Monod-Broca J, Benkerrou M, et al. Generalized periodontitis associated with Ch&eacute;diak-Higashi syndrome. J Periodontol 2008; 79:1263.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/30\" class=\"nounderline abstract_t\">Ishii E, Matui T, Iida M, et al. Chediak-Higashi syndrome with intestinal complication. Report of a case. J Clin Gastroenterol 1987; 9:556.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/31\" class=\"nounderline abstract_t\">Hargis AM, Prieur DJ. Animal model: renal lesions in cats with Chediak-Higashi-Steinbrinck syndrome. Am J Med Genet 1987; 26:169.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/32\" class=\"nounderline abstract_t\">Sung JH, Stadlan EM. Neuropathological changes in Chediak-Higashi disease. J Neuropathol Exp Neurol 1968; 27:156.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/33\" class=\"nounderline abstract_t\">Sung JH, Meyers JP, Stadlan EM, et al. Neuropathological changes in Ch&eacute;diak-Higashi disease. J Neuropathol Exp Neurol 1969; 28:86.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/34\" class=\"nounderline abstract_t\">Misra VP, King RH, Harding AE, et al. Peripheral neuropathy in the Chediak-Higashi syndrome. Acta Neuropathol 1991; 81:354.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/35\" class=\"nounderline abstract_t\">Uyama E, Hirano T, Ito K, et al. Adult Ch&eacute;diak-Higashi syndrome presenting as parkinsonism and dementia. Acta Neurol Scand 1994; 89:175.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/36\" class=\"nounderline abstract_t\">Mathis S, Cintas P, de Saint-Basile G, et al. Motor neuronopathy in Chediak-Higashi syndrome. J Neurol Sci 2014; 344:203.</a></li><li class=\"breakAll\">Rosenzweig SD, Uzel G, Holland S. Phagocytic disorders. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.618.</li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/38\" class=\"nounderline abstract_t\">Rubin CM, Burke BA, McKenna RW, et al. The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 1985; 56:524.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/39\" class=\"nounderline abstract_t\">Merino F, Henle W, Ram&iacute;rez-Duque P. Chronic active Epstein-Barr virus infection in patients with Chediak-Higashi syndrome. J Clin Immunol 1986; 6:299.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/40\" class=\"nounderline abstract_t\">Merino F, Klein GO, Henle W, et al. Elevated antibody titers to Epstein-Barr virus and low natural killer cell activity in patients with Chediak-Higashi syndrome. Clin Immunol Immunopathol 1983; 27:326.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/41\" class=\"nounderline abstract_t\">Barrat FJ, Le Deist F, Benkerrou M, et al. Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation. Proc Natl Acad Sci U S A 1999; 96:8645.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/42\" class=\"nounderline abstract_t\">Jessen B, Maul-Pavicic A, Ufheil H, et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood 2011; 118:4620.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/43\" class=\"nounderline abstract_t\">Blume RS, Bennett JM, Yankee RA, Wolff SM. Defective granulocyte regulation in the Chediak-Higashi syndrome. N Engl J Med 1968; 279:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/44\" class=\"nounderline abstract_t\">Root RK, Rosenthal AS, Balestra DJ. Abnormal bactericidal, metabolic, and lysosomal functions of Chediak-Higashi Syndrome leukocytes. J Clin Invest 1972; 51:649.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/45\" class=\"nounderline abstract_t\">Brahmi Z. Nature of natural killer cell hyporesponsiveness in the Chediak-Higashi syndrome. Hum Immunol 1983; 6:45.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/46\" class=\"nounderline abstract_t\">Klein M, Roder J, Haliotis T, et al. Ch&eacute;diak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J Exp Med 1980; 151:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/47\" class=\"nounderline abstract_t\">Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab 1999; 68:283.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/48\" class=\"nounderline abstract_t\">Tardieu M, Lacroix C, Neven B, et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Blood 2005; 106:40.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/49\" class=\"nounderline abstract_t\">Pettit RE, Berdal KG. Ch&eacute;diak-Higashi syndrome. Neurologic appearance. Arch Neurol 1984; 41:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/50\" class=\"nounderline abstract_t\">Burkhardt JK, Wiebel FA, Hester S, Argon Y. The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes. J Exp Med 1993; 178:1845.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/51\" class=\"nounderline abstract_t\">Ostlund RE Jr, Tucker RW, Leung JT, et al. The cytoskeleton in Chediak-Higashi syndrome fibroblasts. Blood 1980; 56:806.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/52\" class=\"nounderline abstract_t\">Valente NY, Machado MC, Boggio P, et al. Polarized light microscopy of hair shafts aids in the differential diagnosis of Ch&eacute;diak-Higashi and Griscelli-Prunieras syndromes. Clinics (Sao Paulo) 2006; 61:327.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/53\" class=\"nounderline abstract_t\">Diukman R, Tanigawara S, Cowan MJ, Golbus MS. Prenatal diagnosis of Chediak-Higashi syndrome. Prenat Diagn 1992; 12:877.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/54\" class=\"nounderline abstract_t\">de Saint Basile. Chediak-Higashi and Griscelli syndromes. Immunol Allergy Clin North Am 2002; 22:301.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/55\" class=\"nounderline abstract_t\">Di Pietro SM, Dell'Angelica EC. The cell biology of Hermansky-Pudlak syndrome: recent advances. Traffic 2005; 6:525.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/56\" class=\"nounderline abstract_t\">Pierson DM, Ionescu D, Qing G, et al. Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review. Respiration 2006; 73:382.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/57\" class=\"nounderline abstract_t\">Tager AM, Sharma A, Mark EJ. Case records of the Massachusetts General Hospital. Case 32-2009. A 27-year-old man with progressive dyspnea. N Engl J Med 2009; 361:1585.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/58\" class=\"nounderline abstract_t\">Baldus M, Zunftmeister V, Geibel-Werle G, et al. Ch&eacute;diak-Higashi-Steinbrinck syndrome (CHS) in a 27-year-old woman--effects of G-CSF treatment. Ann Hematol 1999; 78:321.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/59\" class=\"nounderline abstract_t\">Aslan Y, Erduran E, Gedik Y, et al. The role of high dose methylprednisolone and splenectomy in the accelerated phase of Ch&eacute;diak-Higashi syndrome. Acta Haematol 1996; 96:105.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/60\" class=\"nounderline abstract_t\">Ayas M, Al-Ghonaium A. In patients with Chediak-Higashi syndrome undergoing allogeneic SCT, does adding etoposide to the conditioning regimen improve the outcome? Bone Marrow Transplant 2007; 40:603.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/61\" class=\"nounderline abstract_t\">Eapen M, DeLaat CA, Baker KS, et al. Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplant 2007; 39:411.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/62\" class=\"nounderline abstract_t\">Haddad E, Le Deist F, Blanche S, et al. Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: report of 10 cases. Blood 1995; 85:3328.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/63\" class=\"nounderline abstract_t\">Sparber-Sauer M, H&ouml;nig M, Schulz AS, et al. Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation. Bone Marrow Transplant 2009; 44:333.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/64\" class=\"nounderline abstract_t\">Nagai K, Ochi F, Terui K, et al. Clinical characteristics and outcomes of ch&eacute;diak-Higashi syndrome: a nationwide survey of Japan. Pediatr Blood Cancer 2013; 60:1582.</a></li><li><a href=\"https://www.uptodate.com/contents/chediak-higashi-syndrome/abstract/65\" class=\"nounderline abstract_t\">Thakor A, Geng B, Liebhaber M, et al. Successful stem cell transplantation in Chediak-Higashi syndrome. J Allergy Clin Immunol Pract 2015; 3:271.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3926 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Accelerated phase</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">LABORATORY FINDINGS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">DIAGNOSIS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">TREATMENT</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">PROGNOSIS</a></li><li><a href=\"#H1481194276\" id=\"outline-link-H1481194276\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H865637202\" id=\"outline-link-H865637202\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ALLRG/3926|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ALLRG/57556\" class=\"graphic graphic_picture\">- CHS smear giant granules</a></li><li><a href=\"image.htm?imageKey=ALLRG/75571\" class=\"graphic graphic_picture\">- Two-year-old female with Chediak-Higashi syndrome</a></li><li><a href=\"image.htm?imageKey=HEME/71313\" class=\"graphic graphic_picture\">- Giant granules in Chediak-Higashi syndrome</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis\" class=\"medical medical_review\">Clinical features and diagnosis of hemophagocytic lymphohistiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-and-acquired-disorders-of-platelet-function\" class=\"medical medical_review\">Congenital and acquired disorders of platelet function</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-disorders-of-phagocytic-function-an-overview\" class=\"medical medical_review\">Primary disorders of phagocytic function: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-immunodeficiency-overview-of-management\" class=\"medical medical_review\">Primary immunodeficiency: Overview of management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-primary-immunodeficiencies\" class=\"medical medical_society_guidelines\">Society guideline links: Primary immunodeficiencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=syndromic-immunodeficiencies\" class=\"medical medical_review\">Syndromic immunodeficiencies</a></li></ul></div></div>","javascript":null}